STOCK TITAN

BriaCell Therapeutics Corp - BCTXW STOCK NEWS

Welcome to our dedicated news page for BriaCell Therapeutics (Ticker: BCTXW), a resource for investors and traders seeking the latest updates and insights on BriaCell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BriaCell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BriaCell Therapeutics's position in the market.

Rhea-AI Summary
BriaCell Therapeutics Corp. updates on the investigation of alleged illegal trading activity of its securities by filing complaints with FINRA and CIRO after identifying significant settlement share imbalances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. reports a preliminary disease control rate of 61% in evaluable Phase 2 advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen in their open pivotal Phase 3 study. Additionally, a disease control rate of 50% was observed in patients who had failed prior antibody-drug conjugate (ADC) therapy. A notable responder who had failed 4 prior therapies, including ADC therapy with a metastatic liver tumor, saw significant improvement following BriaCell treatment. The company is encouraged by the clinical benefits observed and looks forward to sharing additional clinical data in the coming months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
clinical trial
-
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the initiation of Good Manufacturing Practice (GMP) manufacturing of its lead candidate for treating prostate cancer, Bria-Pros+. The company's next generation personalized immunotherapy platform, Bria-Pros+, is capable of activating multiple types of immune cells, including helper T cells, cytotoxic (killer) T cells, and natural killer cells. This represents a major milestone for BriaCell, as GMP manufacturing will provide clinical supplies for planned clinical trial use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
Rhea-AI Summary
BriaCell Therapeutics Corp. announces the results of its annual general meeting of shareholders, with an overwhelming vote in favor of all proposed resolutions. The meeting saw a total of 5,375,071 common shares voted, representing 33.63% of the Company's issued and outstanding Common Shares. Shareholders voted in favor of re-appointing MNP LLP as auditors and authorizing the directors' remuneration, as well as the election of seven directors. The formal report on voting results will be filed on the Company's SEDAR+ profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.19%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (BCTX) reports significant reduction in metastatic breast cancer tumor behind the eye after 3 cycles of Bria-IMT™ combination regimen. The patient had failed 7 prior regimens, including antibody-drug conjugate therapy, and experienced reduced proptosis and ocular pain. Bria-IMT™ showed robust anti-tumor activity in difficult-to-reach tumors, with a 71% intracranial objective response rate in breast cancer patients with CNS metastases. The pivotal Phase 3 study in advanced breast cancer is ongoing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.6%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reports 71% intracranial objective response rate (iORR) in advanced breast cancer patients with CNS metastases treated with Bria-IMT™ regimen, demonstrating clinical efficacy and potential market approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
none
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT™ regimen. Overall Survival (OS) data exceeded similar studies, with a median OS up to twice that reported in the literature. Progression Free Survival (PFS) was similar or better than the last regimen in 40% of the patients, and a disease control rate of 40% was observed in evaluable patients, further indicating clinical benefit.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announced outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated with Bria-IMT™ in combination with an immune check point inhibitor. The median overall survival was 13.4 months, a marked improvement over the benchmark of 6.7-9.8 months for similar patients. 32 out of 42 patients treated since 2022 remain alive, indicating consistently strong survival benefit. All patients were able to receive therapy with no toxicity-related discontinuations. The Phase 2 study is fully enrolled with 54 advanced metastatic breast cancer patients, showing excellent overall survival and tolerability, as well as a positive immune response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) is presenting findings at the 2023 San Antonio Breast Cancer Symposium, demonstrating the effectiveness of their Bria-IMT™ combination regimen in activating cancer-fighting T cells and producing unique antibody responses in patients with disease control. Advanced CD8 ImmunoPET imaging showed the transformation of cold immune suppressed tumors to hot immune responsive ones, indicating the potential of the treatment in cancer patients. The company also plans to present updated overall survival clinical data, showing significant anti-tumor activity of Bria-IMT™ in advanced metastatic breast cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
Rhea-AI Summary
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) announces a remarkable responder in their Phase 2 study of the Bria-IMT™ combination regimen. A patient with extensive metastatic breast cancer behind the eye experienced a remarkable improvement of eye-bulging 'proptosis' and significant pain reduction after only 3 cycles of treatment. The patient had previously failed 7 regimens and continues to receive treatment. Additional survival updates and clinical data sets will be presented at the San Antonio Breast Cancer Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
none
BriaCell Therapeutics Corp

Nasdaq:BCTXW

BCTXW Rankings

BCTXW Stock Data

11.64M
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Canada
West Vancouver

About BCTXW

briacell therapeutics corp immunotherapy approaches to cancer management briacell is a los angeles headquartered biotechnology company focused on immunotherapy treatments for cancer management. to date, the company has been successful in developing its patented "briavax" vaccine and implementing two compelling fda phase-i studies with late-stage breast cancer patients, demonstrating unique and unprecedented results. briacell is focused on aggressively moving towards launching its next clinical trial, a phase-i/ii study, in order to apply its vaccine to a larger number of breast cancer patients and effectively progress its technology along the value chain. while the current corporate focus is breast cancer, the company has an eye towards potentially applying its vaccine technology to certain other cancer types as well.